Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year

 
 

Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the national benchmarking tool measuring policies, practices and benefits pertinent to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees, the CEI is a driving force for LGBTQ+ workplace inclusion.

 
 

  HRC Corporate Equality Index 2022 

 
 

"We truly believe that embracing diverse backgrounds and perspectives is vital to our long-term success as we work toward our shared mission of enabling our customers to make the world healthier, cleaner and safer," said Jennifer Farmer , vice president, global diversity and inclusion at Thermo Fisher Scientific. "Fostering an inclusive culture and a sense of belonging for our colleagues empowers them to contribute their best ideas and bring their true selves to work each day."

 

In 2002, the first year of the CEI, only 13 companies achieved a top-score. A record-breaking 842 businesses earned 100 percent on the 2022 CEI and the designation of being one of the "Best Places to Work for LGBTQ Equality," demonstrating the incredible impact the CEI has had on the business world over the last 20 years.

 

The CEI report measures performance across four categories, from the adoption of inclusive non-discrimination policies and equitable healthcare benefits for transgender employees to supporting an inclusive culture and corporate social responsibility. Thermo Fisher's perfect score of 100 is based on its commitment to success within each of these important areas.

 

To view the full 2022 Corporate Equality Index report, visit www.hrc.org/cei . To learn more about Thermo Fisher's commitment to employee involvement, please click here .

 

  About Thermo Fisher Scientific  
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

 

Media Contact Information:
Charlotte McCormack
Phone: 781-622-1202
E-mail: charlotte.mccormack@thermofisher.com  

 

Investor Contact Information:
Rafael Tejada  
Phone:  781-622-1356 E-mail:
rafael.tejada@thermofisher.com  

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-earns-top-score-for-lgbtq-workplace-equality-for-seventh-consecutive-year-301470112.html  

 

SOURCE Thermo Fisher Scientific

 
 

News Provided by PR Newswire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×